

Meningococcal Vaccines—High-risk Populations

Different vaccines protect against different serogroups.

Risk groups:

- Exp.** Increased Exposure to meningococcal serogroups covered by vaccines (due to outbreaks¹, travel to affected areas [e.g. the Hajj], lab exposure)
- CD.** Persistent Complement component Deficiencies (including persons taking eculizumab [Soliris[®]])
- Asp.** Functional or Anatomic Asplenia (including sickle cell disease)
- HIV.** HIV Infection

Age at first dose	Exp	CD	Asp	HIV	1) MenACWY vaccines ²	Boosters for those who remain at increased risk
2–6 months	✓	✓	✓	✓	2 months: ACWY-CRM Menveo [®] 4 months: ACWY-CRM Menveo [®] 6 months: ACWY-CRM Menveo [®] 12–15 months: ACWY-CRM ³ Menveo [®]	If primary dose(s) given when younger than 7 years: 3 years → ACWY-CRM or -D ⁵ Menveo [®] or Menactra [®] → Every 5 years → ACWY-CRM or -D Menveo [®] or Menactra [®]
7–23 months	✓	✓	✓	✓	ACWY-CRM Menveo [®] → 3 months → ACWY-CRM ³ Menveo [®]	
9–23 months	✓	✓			ACWY-D ^{4,5,6} Menactra [®] → 3 months → ACWY-D ^{3,6} Menactra [®]	
2 years and older		✓	✓ ⁵	✓ ⁵	ACWY-CRM or -D ^{5,6} Menveo [®] or Menactra [®] → 2 months → ACWY-CRM or -D ⁶ Menveo [®] or Menactra [®]	
		✓			ACWY-CRM or -D ^{5,6} Menveo [®] or Menactra [®]	
2) Also give MenB vaccine—may be given at same time as MenACWY vaccine. Use the same brand for each dose in the series.						
10 years and older	✓	✓	✓		1st dose: MenB-4C Bexsero [®] → 1 month → 2nd dose: MenB-4C Bexsero [®]	OR 1st dose: MenB-FHbp Trumenba [®] → 1–2 months → 2nd dose: MenB-FHbp Trumenba [®] → 6 months between 1st and 3rd dose → 3rd dose: MenB-FHbp Trumenba [®]
					1st dose: MenB-FHbp Trumenba [®] → 1–2 months → 2nd dose: MenB-FHbp Trumenba [®] → 6 months between 1st and 3rd dose → 3rd dose: MenB-FHbp Trumenba [®]	

For further details, see www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html. For routine use, see recommendations at EZIZ.org/assets/docs/IMM-1217.pdf.

- For information on current meningococcal outbreaks, see www.cdph.ca.gov/HealthInfo/discond/Pages/MeningococcalDisease.aspx
- Abbreviations: ACWY/ACWY-CRM/ACWY-D = MenACWY = MCV4
- Minimum age 12 months.
- MenACWY-D (Menactra[®]) is licensed starting at 9 months.
- If MenACWY-D (Menactra[®]) is used for persons with asplenia or HIV infection, defer until age 2 years and at least 4 weeks after completion of PCV13 series.
- It is recommended that MenACWY-D be given either before, or concomitantly with, the next recommended dose of DTaP vaccine.

